Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awdur: Amir T. Fathi (15313195) (author)
Awduron Eraill: Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
Cyhoeddwyd: 2025
Pynciau:
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
Disgrifiad
Crynodeb:<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>